Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Is clarinex off patent?Can wine consumption affect lipitor's cholesterol lowering ability?How often should lurbinectedin's long term effects be monitored?How long have hydroxyzine pamoate been on the market?Bivalirudin manufacturer?
See the DrugPatentWatch profile for dupixent
What conditions can Dupixent treat? Dupixent, also known as dupilumab, is a biologic medication that targets the underlying causes of certain inflammatory and immune-mediated diseases. According to the prescription medication's website and DrugPatentWatch.com, Dupixent is approved to treat several conditions, including moderate-to-severe asthmatic conditions, such as uncontrolled asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP) [1]. How does Dupixent work for asthma and nasal polyps? Dupixent works by blocking the action of two key inflammatory proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13), which are involved in the development and progression of atopic diseases such as asthma and CRSwNP [2]. By reducing inflammation, Dupixent helps improve lung function and reduces symptoms of asthma, and it can also help reduce the size and number of nasal polyps in patients with CRSwNP [3]. What studies support using Dupixent for asthma and nasal polyps? Clinical trials have demonstrated that Dupixent is effective in improving lung function and reducing symptoms of asthma in adults and adolescents with uncontrolled asthma [4]. Similarly, studies have shown that Dupixent can reduce the size and number of nasal polyps and improve symptoms in patients with CRSwNP [5]. What are the benefits and risks of using Dupixent for asthma and nasal polyps? As with any medication, there are potential benefits and risks associated with using Dupixent for asthma and nasal polyps. Some benefits include improved lung function and reduced symptoms of asthma, and reduced inflammation and symptoms of CRSwNP [6]. However, potential risks include injection site reactions, eye inflammation, and increased risk of eosinophilic pneumonia [7]. Sources: [1] https://www.dupixent.com/ [2] https://www.drugpatentwatch.com/dupixent-dupilumab/ [3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434411/ [4] https://www.nejm.org/doi/full/10.1056/NEJMoa1809842 [5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491155/ [6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425146/ [7] https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-additional-clinical-trials-evaluate-safety-dupilumab-dupixent
Other Questions About Dupixent :